Amicus Therapeutics, Inc. (FOLD) - NASDAQ
  • Tue, May 31, 9:15 AM
    | Tue, May 31, 9:15 AM | 2 Comments
  • Fri, May 20, 7:32 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $12 (140% upside) price target by Chardan Capital.
    • Amicus Therapeutics (NASDAQ:FOLD) initiated with Buy rating and $10 (45% upside) price target by Bank of America.
    • Quorum Health (NYSE:QHC) initiated with Equal Weight rating and $12 (2% upside) price target by Morgan Stanley.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $56 (30% upside) price target by Credit Suisse.
    • Prothena (NASDAQ:PRTA) initiated with Overweight rating and $60 (47% upside) price target by Barclays.
    • Mazor Robotics (NASDAQ:MZOR) upgraded to Outperform from Market Perform by Wells Fargo. Price target raised to $15-17 (14% upside from midpoint) from $10-13.
    • Eli Lilly (NYSE:LLY) upgraded to Strong Buy with a price target of $88.67 (19% upside) by the Vetr Community.
    • Haemonetics (NYSE:HAE) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $29 (5% upside) from $25.
    • Nanosphere (NASDAQ:NSPH) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $1.35 (2% upside) from $2.00.
    • Anacor Pharmaceuticals (NASDAQ:ANAC) downgraded to Neutral from Buy by Mizuho Securities. Price target set at $99.25 (0% upside).
    • Globus Medical (NYSE:GMED) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $21 (10% downside risk) from $26.
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $0.75 (27% upside).
    | Fri, May 20, 7:32 AM | 10 Comments
  • Tue, May 3, 9:55 AM
    • Amicus Therapeutics (FOLD -2.8%) Q1 results: Revenues: $0; R&D Expense: $23.4M (+45.3%); SG&A: $15.7M (+145.3%); Operating Loss: ($43M) (-78.4%); Net Loss: ($43.7M) (-79.8%); Loss Per Share: ($0.35) (-40.0%); Quick Assets: $165.9M (-22.5%).
    • 2016 Guidance: Net Cash Spend: $135M - 155M.
    | Tue, May 3, 9:55 AM
  • Tue, May 3, 7:04 AM
    | Tue, May 3, 7:04 AM
  • Tue, Apr. 12, 9:27 AM
    • Amicus Therapeutics (NASDAQ:FOLD) is up 7% premarket on robust volume in apparent response to Chardan Capital's increase in its price target to $15 (92% upside) from $10 saying the company is an attractive buyout target.
    • The company's lead product candidate, pharmacological chaperone migalastat, is poised for regulatory approval in the EU for the treatment of Fabry disease after a positive CHMP vote on April 1.
    • Previously: European Ad Comm backs Amicus Therapeutics' migalastat for Fabry disease; shares up 10% (April 1)
    | Tue, Apr. 12, 9:27 AM | 1 Comment
  • Tue, Apr. 12, 9:12 AM
    | Tue, Apr. 12, 9:12 AM
  • Fri, Apr. 1, 12:07 PM
    • Amicus Therapeutics (FOLD +10.1%) is up on increased volume in response to its announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of migalastat for the first-line treatment of Fabry disease patients who have amenable genetic mutations in alpha-Gal A, a lipid substrate-degrading enzyme whose deficiency is the cause of Fabry.
    • Migalastat is a small molecule pharmacological chaperone that enables certain Fabry patients to utilize their own alpha-Gal A instead of relying on enzyme replacement therapy, the current standard of care.
    • A final decision from the European Commission usually takes ~60 days.
    • The company will host a conference call at 12:30 pm ET to discuss the CHMP opinion.
    • Now read This Week in Pharma: Questions on Amicus' Migalastat And AcelRx's ARX-04
    | Fri, Apr. 1, 12:07 PM | 4 Comments
  • Fri, Mar. 18, 12:56 PM
    • Vitae Pharmaceuticals (VTAE +8.2%) upgraded to Buy from Hold by Stifel. Price target set at $15 (105% upside).
    • Johnson & Johnson (JNJ +0.8%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $112 (4% upside) from $102.
    • HCA Holdings (HCA +2.8%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $85 (12% upside) from $76.
    • Epizyme (EPZM +9.8%) upgraded to Buy from Neutral by H.C. Wainwright. Price target raised to $25 (127% upside) from $22.
    • Agenus (AGEN +2.7%) upgraded to Buy from Hold with a $7 (81% upside) price target by Maxim Group.
    • Juno Therapeutics (JUNO +2.6%) upgraded to 4.5 stars (out of a possible 5.0) by the Vetr Community. The implied price target is $45.47 (17% upside).
    • Alnylam Pharmaceuticals (ALNY +3.2%) upgraded to Overweight from Neutral by JP Morgan. Price target lowered to $81 (37% upside) from $111.
    • Amicus Therapeutics (FOLD +4.3%) upgraded to Buy from Neutral by Janney Capital. Price target raised to $12 (59% upside) from $10.
    • Pernix Therapeutics Holdings (PTX -5%) downgraded to Market Perform from Outperform by Oppenheimer. $9 price target removed.
    • Valeant Pharmaceuticals (VRX -6.6%) downgraded to Neutral from Buy by Nomura. Price target lowered to $60 (116% upside) from $175. Morgan Stanley maintains Equal Weight rating but lowers price target to $39 (40% upside) from $98. Stifel rates it a Buy but lowered its price target to $65 (134% upside) from $200. Rodman & Renshaw rates it a Buy with a $118 (324% upside) price target (from $150). Piper Jaffray downgraded it to Underweight from Neutral with no price target.
    • AstraZeneca (AZN -1.5%) downgraded to Hold from Buy by Jefferies. Price target lowered to 4,350p (12% upside) from 4,900p.
    • Cardinal Health (CAH +1.4%) and McKesson (MCK +4.4%) both downgraded to Market Perform from Outperform by Cowen & Company. Price targets lowered to $90 (11% upside) and $173 (9% upside), respectively.
    | Fri, Mar. 18, 12:56 PM | 26 Comments
  • Wed, Mar. 9, 10:35 AM
    • Ultragenyx (RARE -1.5%) initiated with Outperform rating and $85 (44% upside) price target by Baird.
    • BioMarin Pharmaceutical (BMRN -1.6%) initiated with Outperform rating and $110 (33% upside) price target by Baird.
    • Nanosphere (NSPH +1.1%) initiated with Buy rating and $2 (117% upside) price target by Rodman & Renshaw.
    • BioSpecifics Technologies (BSTC -0.9%) initiated with Buy rating and $60 (68% upside) price target by Rodman & Renshaw.
    • Proteostasis Therapeutics (PTI +7.5%) initiated with Buy rating and $15 (67% upside) price target by H.C. Wainwright. Initiated with Outperform rating and $20 (122% upside) price target by RBC Capital. Initiated with Outperform rating and $13 (44% upside) price target by Baird.
    • AveXis (AVXS -0.8%) initiated with Outperform rating and $31 (44% upside) price target by BMO Capital. Initiated with Buy rating and $28 (30% upside) price target by Goldman Sachs.
    • Delcath Systems (DCTH +2.8%) initiated with Buy rating and $1 (233% upside) price target by WallachBeth.
    • Amicus Therapeutics (FOLD -1.8%) upgraded to Buy from Neutral by Janney Capital. Price target raised to $12 (61% upside) from $10.
    • Celldex Therapeutics (CLDX +1.4%) downgraded to Hold from Buy by Jefferies. Price target lowered to $4 (10% upside) from $31.
    • MEDNAX (MD -0.2%) downgraded to Neutral from Positive by Susquehanna. Price target lowered to $70 (8% upside) from $94.
    • Roka Bioscience (ROKA -8.8%) downgraded to Market Perform from Outperform. Price target lowered to $1 (22% upside).
    • Zimmer Biomet Holdings (ZBH +0.1%) downgraded to Hold from Buy by Argus Research.
    | Wed, Mar. 9, 10:35 AM | 5 Comments
  • Tue, Mar. 1, 9:11 AM
    • Amicus Therapeutics (NASDAQ:FOLD) is up 12% premarket on light volume in response to its announcement of new Phase 3 results on migalastat in Fabry disease as well as encouraging preclinical data on its candidate for Pompe disease. The data were presented at the WORLDSymposium 2016 in San Diego, CA.
    • Results from Study 011, called FACETS, in Fabry patients who were naive to enzyme replacement therapy (ERT) and treated with migalastat showed a statistically significant reduction in disease substrate (GL-3) in podocytes from baseline to Month 6 (p=0.02). Podocytes are cells in the kidneys that play a key role in filtering the blood in the early phase of forming urine. GL-3 (globotriaosylceramide) is a type of fat that accumulates in the cells of Fabry sufferers.
    • Data from Study 012, called ATTRACT, showed the effects from migalastat on kidney and cardiac function persisted from the primary treatment period (0-18 months) through the open-label extension phase (19-30 months) in amenable patients who switched from ERT to migalastat.
    • Fabry disease is caused by mutations in an enzyme called alpha-galactosidase A which is responsible for metabolizing GL-3 and prevents it from accumulating in cells.
    • Preclinical data were also presented on the company's novel treatment for Pompe disease, ATB200/AT2221, that showed increased tissue enzyme levels and reduced substrate in models of skeletal muscle. ATB200 is a recombinant human acid alpha-glucosidase enzyme that is engineered for enhanced uptake. AT2221 is a pharmacological chaperone that improves activity and stability.
    • Pompe disease is a rare genetic disorder characterized by the buildup of the sugar molecule glycogen in the body's cells. It is caused by mutations in an enzyme called alpha-glucosidase, which is responsible for the breakdown of glycogen into glucose.
    | Tue, Mar. 1, 9:11 AM
  • Fri, Feb. 26, 9:17 AM
    | Fri, Feb. 26, 9:17 AM | 7 Comments
  • Fri, Feb. 26, 7:04 AM
    | Fri, Feb. 26, 7:04 AM
  • Nov. 3, 2015, 4:04 PM
    • Amicus Therapeutics (NASDAQ:FOLD): Q3 EPS of -$0.32 misses by $0.07.
    | Nov. 3, 2015, 4:04 PM | 1 Comment
  • Oct. 9, 2015, 10:00 AM
    • Thermo Fisher Scientific (TMO +0.3%) initiated with Buy rating and $145 (15% upside) price target by Argus.
    • Fate Therapeutics (FATE +0.4%) initiated with Outperform rating and $8 (41% upside) price target by Raymond James.
    • Ocata Therapeutics (OCAT +2.1%) initiated with Outperform rating and $8 (66% upside) price target by Raymond James.
    • Eli Lilly (LLY +2.8%) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $105 (22% upside) from $89.
    • Abbott Laboratories (ABT +1%) upgraded to Overweight from Equal Weight by Barclays. Price target lowered to $52 (26% upside) from $55.
    • NuVasive (NUVA -1.6%) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $58 (16% upside) from $52.
    • Amicus Therapeutics (FOLD +5.4%) upgraded to Buy from Neutral with an $8 (11% upside) price target by Chardan Capital.
    • Bluebird bio (BLUE +1.5%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target maintained at $143 (61% upside).
    • Pfizer (PFE +0.5%) upgraded to Outperform from Equal Weight by Morgan Stanley. Price target raised to $38 (15% upside) from $35.
    • Vertex Pharmaceuticals (VRTX +1.2%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $148 (35% upside) from $118.
    • Alexion Pharmaceuticals (ALXN -0.2%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $211 (29% upside) from $186.
    | Oct. 9, 2015, 10:00 AM | 12 Comments
  • Oct. 5, 2015, 9:18 AM
    | Oct. 5, 2015, 9:18 AM | 4 Comments
  • Oct. 2, 2015, 12:40 PM
    | Oct. 2, 2015, 12:40 PM | 3 Comments
Company Description
Amicus Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for the treatment of rare diseases, pharmacological chaperones are a novel, first-in-class... More
Sector: Healthcare
Industry: Biotechnology
Country: United States